I am delighted to announce that we will be hosting the 46th Annual Meeting of the Japanese Environment Mutagen Society (JEMS) on November 6 and 7, 2017 at the Hitotsubashi Hall in Tokyo.

Modern society has received a great benefit from industrialization and developed progressively. On the other hand, because of advances in the use of chemicals in society, there are many chemical substances that threaten our lives. Damage to a wide variety of genes is one of these menaces. Currently, most of the possible carcinogens that adversely affect genomic DNA are eliminated with an established system that uses a combination of various genotoxicity assays (battery). It is no exaggeration to say that the history of JEMS Japan was truly representative of research for genomic damage, including mechanisms of DNA damage and establishment of assay systems to appropriately evaluate damage. Our approaches have been appreciated as regulatory science and contributed to the evaluation of pharmaceuticals, foods, agricultural chemicals, and chemical substances.

The theme of this meeting has been set as "Diversified and Sophisticated Genotoxicity Assessment; Its Role and Interpretation". It is time to take a good look at the role and interpretation of diversifying and sophisticating genotoxicity evaluation. New assessment approaches with in vitro and in silico methods, as well as development of brand new mutation analysis technologies, have been astonishing. By contrast, I believe this is also a prime opportunity to focus our attention on in vivo genotoxicity assays, to sit back and discuss afresh about the importance of in vivo genotoxicity assays and their role in predicting human carcinogens, particularly in the context of extensive moves towards international animal protection.

As part of our discussions, we will hold a joint symposium with Safety Evaluation Forum "Significance of genotoxic evaluation in pharmaceutical dvelopment. -Requests from toxicologists-" (tentative title) and a panel discussion "Q&A for genotoxic evaluation from a viewpoint of pharmaceutical development." (tentative title).

A special session will be held on a mind-blowing article in Nature in June 2015. This article described a new mechanism of carcinogenesis which is induced by micronuclei, i.e., “Chromothripsis”, by DNA analysis of a single cell and live-cell imaging. We invited Dr. Alexander Spektor for his lecture on "Chromosome segregation errors and chromothripsis in cancer pathogenesis." This is the best opportunity to hear about the relationship between micronucleus induction, which is a key marker of genotoxicity, and carcinogenicity, which is one of the goals of genotoxicity evaluation.

Besides the above, poster and oral presentations on the latest research will be given by JEMS members. We will be incorporating “flash talks” for poster presentations, which will facilitate participation of young researchers. We are looking forward to many people taking this opportunity to attend the meeting as we are planning a variety of programs that will be of interest to all researchers of industry, government and academic backgrounds.

November 2016
46th JEMS Annual Meeting
Shuichi Hamada
  濱田 修一

Program Outline

The 46th Annual Meeting of the Japanese Environmental Mutagen Society (JEMS)
"Diversified and Sophisticated Genotoxicity Assessment; Its Role and Interpretation"


November 6 – 7, 2017


Hitotsubashi Hall, Tokyo
2-1-2 Hitotsubashi, Chiyoda-ku, Tokyo 101-8439


Shuichi Hamada, Ph.D.
LSI Medience Corporation

Organizing Committees

Satoru Itoh (DAIICHI SANKYO Co., Ltd.)
Yoshifumi Uno (Mitsubishi Tanabe Pharma Corporation)
Wakako Ohyama (Yakult Honsha Co., Ltd.)
Hiroyuki Kamiya (Hiroshima University)
Kei-ichi Sugiyama (National Institute of Health Sciences)
Takayoshi Suzuki (National Institute of Health Sciences)
Yukari Totsuka (National Cancer Center Japan)
Tsuneo Hashizume (Axcelead Drug Discovery Partners, Inc.)
Masamitsu Honma (National Institute of Health Sciences)
Kenichi Masumura (National Institute of Health Sciences)
Masayuki Mishima (Chugai Pharmaceutical Co., Ltd.)
Takeshi Morita (National Institute of Health Sciences)

Program Outline



"Chromosome segregation errors and chromothripsis in cancer pathogenesis."
Chair: David Kirkland (Kirkland Consulting), Shuichi Hamada (LSI Medience Corporation)
Alexander Spektor, M.D., Ph.D.
Alexander Spektor, M.D., Ph.D.
(Harvard Medical School)

JEMS Award Ceremony and Lectures

Chair: Yoshifumi Uno (Mitsubishi Tanabe Pharma Co.)

JEMS Award 2017
"Significance of DNA repair mechanisms in the suppression of oxidative stress-induced mutagenesis and tumorigenesis in mammals."
Teruhisa Tsuzuki (Kyushu University, Present address: Fukuoka Dental College)
Teruhisa Tsuzuki
JEMS Encouragement Award 2017
"Visualization and quantitative analysis of DNA damage response."
Shun Matsuda (FUJIFILM Co.)
Shun Matsuda
JEMS Service Award 2017
"Contributions to optimization of genotoxicity testing procedures and international standardization of them."
Takeshi Morita (National Institute of Health Sciences)
Takeshi Morita

Symposium 1

“DNA damage-induced mutagenesis and its suppression.”
Chair: Hiroyuki Kamiya (Hiroshima University) and Yuji Masuda (Nagoya University)

1) “DNA damage-induced mutagenesis and its suppression.”
Hiroyuki Kamiya (Hiroshima University)
Hiroyuki Kamiya
2) “Regulation of DNA polymerase η in translesion DNA synthesis of UV-induced DNA damage.”
Yuji Masuda, Rie Kanao, Chikahide Masutani
(Nagoya University)
Yuji Masuda
3) “Analysis of mutations arisen from bulky DNA adducts in the cells lacking the nucleotide excision repair and various TLS polymerases, which were established by genome editing.”
Takashi Yagi1, Yoshihiro Fujikawa1,2, Kodai Fukumoto1, Akane Takenokuchi1, Takeji Takamura-Enya3, Masanobu Kawanishi1
(1Osaka Prefecture University, 2Present: Osaka University, 3Kanagawa Institute of Technology)
Takashi Yagi
4) “DNA-protein cross-links: Detection and biological effects.”
Hiroshi Ide (Hiroshima University)
Hiroshi Ide
5) “The action mechanism and possible application of small molecules destabilizing DNA repair factors.”
Tsukasa Matsunaga (Kanazawa University)
Tsukasa Matsunaga

Symposium 2 (International Session)

“Recent topics of genotoxicity strategy in drug discovery.”
Chair: Tsuneo Hashizume (Axcelead Drug Discovery Partners),Hans-Joerg Martus (Novartis)

1) “Trends in genotoxicity assessment in drug discovery.”
Hans-Joerg Martus (Novartis)
Hans-Joerg Martus
2) “In silico prediction coupled with expert interpretation for assessment of mutagenicity in drug discovery.”
Atsushi Hakura, Naoki Koyama, Naoki Toritsuka, Shoji Asakura
Atsushi Hakura
3) “Generalizability of the MultiFlow® DNA Damage Assay and Three Companion Machine Learning Models Investigated with a Set of 54 Diverse Chemicals”
Stephen D. Dertinger (Litron)
Stephen D. Dertinger
4) “Risk mitigation of genotoxicity liability at drug discovery space”
Kiyohiro Hashimoto (Takeda Pharmaceutical Co. Ltd.)
Kiyohiro Hashimoto

Symposium 3

“New era of environmental mutagenesis -epigenetics and de novo mutation-”
Chair: Kenichi Masumura (National Institute of Health Sciences),Kei-ichi Sugiyama (National Institute of Health Sciences)

1) “Detection of inherited germline mutations as de novo mutations.”
Kenichi Masumura (National Institute of Health Sciences)
Kenichi Masumura
2) “Somatic mosaic mutations cause human diseases.”
Naomichi Matsumoto (Yokohama City University)
Naomichi Matsumoto
3) “Epigenetic disturbance induced by environmental factors and its control for cancer prevention.”
Naoko Hattori, Eriko Okochi-Takada, Tohru Niwa, Toshikazu Ushijima
(National Cancer Center Research Institute)
Naoko Hattori
4) “Development of detection system for epigenetic mutagen.”
Kei-ichi Sugiyama (National Institute of Health Sciences)
Kei-ichi Sugiyama

Symposium 4

Joint Symposium with Safety Evaluation Forum
“Significance of genotoxic evaluation in pharmaceutical development -Requests from toxicologists-”
Chair: Takeshi Morita (National Institute of Health Sciences), Yuji Kawamura (Meiji Seika Pharma Co., Ltd.)

1) “Toxicologist and genotoxicologist.”
Masamitsu Honma (National Institute of Health Sciences)
Masamitsu Honma
2) “Genotoxicity interpreted by pathological viewpoints.”
Kumiko Ogawa, Young-Man Cho, Yuji Ishii, Takeshi Toyoda
(National Institute of Health Sciences)
Kumiko Ogawa
3) “Micronucleus: Implication of carcinogenesis and perspectives in genotoxicity testing.”
Takeshi Morita (National Institute of Health Sciences), Shuichi Hamada (LSI Medience Co.)
Takeshi Morita
4) “Impact of genotoxicity testing results on pharmaceutical development.”
Yoshifumi Uno (Mitsubishi Tanabe Pharma Co.)
Yoshifumi Uno
5) “Q&A for genotoxic evaluation from a viewpoint of pharmaceutical development.”
Facilitator: Makoto Miyauchi (Mochida Pharmaceutical Co., Ltd.)
Makoto Miyauchi (Mochida Pharmaceutical Co., Ltd.), Yuji Kawamura (Meiji Seika Pharma Co., Ltd.), Akira Koda (Maruho Co., Ltd.), Asuka Takumi (Ajinomoto Co., Inc.), Yutaka Yonezawa (Kaken Pharmaceutical Co., Ltd.), Kazuma Kondo (Japan Tobacco Inc.), Yoshihiro Nishiyama (Kowa Company. Ltd.), Yuko Arie (Wakamoto Pharmaceutical Co., Ltd.), Masafumi Doi (Daiichi Sankyo RD Novare co., Ltd.)
Makoto Miyauchi

Poster Session(Flash Talk)

Chair:Kazunori Narumi (Yakult Central Institute) ,Takafumi Kimoto (Teijin Pharma Limited)


Evening, November 6, 2017
Josui Kaikan

2-1-1 Hitotsubashi, Chiyoda-ku, Tokyo 101-0003

Call for Abstract

July 6- Aug 25, 2017 (JST)
Sep 8, 2017 Noon (JST) Extent

If you wish to submit, please contact us E-mail:

Poster and Flash Talk Presentation

【Poster Presentation】
The poster size should be 200cm long and 90cm wide or smaller.
We will display 20cm×20cm sized your poster number in the corner of left above, please be aware of the space.

【Flash Talk】
A flash talk (lightning talk) is a short oral presentation, in which presenters have one minute to briefly present a scientific concept or idea with one slide prior to their poster presentation. This helps presenters to draw attention to their poster presentations, and also helps audiences to easily find poster presentations of their interest.
  • Presentation time:1min
  • Your presentation data is ready at the presentation room in advance

Data preparation:
We will accept the data with PDF format via e-mail, please refer the sample template below.
Flash Talk presentation format
  • One slide only
  • No animation, movie and audio
  • Save as PDF file
  • Do not change a color, font size and layout in the title area
  • The file should be named “Program number_Presenter’s name”
    i.e.) 64_Hironao Takasawa.pdf

Data Submission:
  • Submission period: October 3 (Tue)-October 20 (Fri), 2017    Closed
  • We cannot accept the replacement of the data after submission
  • Send to Congress Management Office


Registration Fee

Category Early Registration
(Until Noon, Sep 29, 2017)
Member 11,000 JPY 13,000 JPY
Student Member 3,000 JPY 5,000 JPY
Non-member(Student) 5,000 JPY 7,000 JPY
Non-member(Regular) 13,000 JPY 15,000 JPY
Banquet Member 8,000 JPY 10,000 JPY
Student Member 4,000 JPY 6,000 JPY
Non-member(Student) 5,000 JPY 7,000 JPY
Non-member(Regular) 9,000 JPY 11,000 JPY

Early Registration

Early registration:  July 6- Sep 29, 2017 at Noon (JST)


Nonclinical Research Center
Drug Development Service Segment LSI Medience Corporation
14-1 Sunayama, Kamisu-shi, Ibaraki-ken 314-0255, Japan